search
Back to results

Evaluation of the Effectiveness and Safety of Supratube Device (SUPRANAV)

Primary Purpose

Intensive Critical Unit, Pneumonia, Aspiration

Status
Completed
Phase
Not Applicable
Locations
Colombia
Study Type
Interventional
Intervention
Supranav
Sponsored by
Fundación Cardiovascular de Colombia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Intensive Critical Unit

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Intubated adult patients with mechanical ventilation.
  • To have a closest responsible relative
  • Integrity of the airways

Exclusion Criteria:

  • Need of orofacial, cervical or respiratory tract surgical procedures
  • Patients with tracheostomy
  • Shock,
  • Local or systemic uncontrolled infection
  • Blood dyscrasia, neoplastic diseases
  • Physiological alteration
  • Acute or chronic decompensated pathology that is not controlled at the time of selection.

Sites / Locations

  • Fundación Cardiovascular de Colombia

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Control

Supranav

Arm Description

Usual respiratory care

Respiratory care with "supranav" which is a continuous supraglottic suction device

Outcomes

Primary Outcome Measures

Ventilator associated events
A group of all the conditions that result in a significant and sustained deterioration in oxygenation, defined as a greater than 20% increase in the daily minimum fraction of inspired oxygen or an increase of at least 3 cm H2O in the daily minimum positive end-expiratory pressure (PEEP) to maintain oxygenation. It is imperative to understand that both infectious conditions (such as tracheitis, tracheobronchitis, and pneumonia) and noninfectious conditions (such as atelectasis, pulmonary embolism, pulmonary edema, ventilator-induced lung injury, and others) may fulfill this VAE definition.

Secondary Outcome Measures

Adverse events
Number of patientes with Bleeding and lacerations in the oropharynx

Full Information

First Posted
May 10, 2018
Last Updated
April 18, 2022
Sponsor
Fundación Cardiovascular de Colombia
search

1. Study Identification

Unique Protocol Identification Number
NCT03573609
Brief Title
Evaluation of the Effectiveness and Safety of Supratube Device
Acronym
SUPRANAV
Official Title
Multicenter, Controlled, Randomized Clinical Trial to Evaluate the Effectiveness and Safety of the New Supratube Invention Device to Prevent Pneumonia Associated With Mechanical Ventilation: " Supra-nav Project "
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
May 29, 2018 (Actual)
Primary Completion Date
December 1, 2019 (Actual)
Study Completion Date
January 20, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundación Cardiovascular de Colombia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Purpose of the trial: Trial design: Two-parallel arm, double-blind, individually randomized controlled trial. Primary endpoint: Clinical evaluation of sinus, oropharyngeal, tracheal, bronchial or pulmonary infections during orotracheal intubation and hospital admission. Secondary endpoints: Volume of oropharyngeal secretions aspirated per unit of time (for 24 hours) by the SupraTube and Complications during the use of the SupraTube device: erosions, lacerations, Bleeding, displacement, migration, need for withdrawal. Inclusion criteria: Adult patient Orotracheal intubation ≤ 72 hours Hospitalized in ICU integrity of upper airways Exclusion criteria: International patients Coagulopathic patients oncology patients patients with maxillofacial surgery Absence of close responsible family member Tracheostomy, shock, local or systemic non-controlled infection Trial treatment: Intervention: Aspiration of secretions with the supranav device Control: Usual respiratory care Expected sample size, enrollment and expected number of centers: Sample size = 108 Recruitment start date: Recruitment end date: Follow-up end date: Number of centers: 2 Statistical considerations: Intention to treat analysis The primary outcomes will be analyzed using

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intensive Critical Unit, Pneumonia, Aspiration, Prevention and Control

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
108 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Usual respiratory care
Arm Title
Supranav
Arm Type
Active Comparator
Arm Description
Respiratory care with "supranav" which is a continuous supraglottic suction device
Intervention Type
Device
Intervention Name(s)
Supranav
Intervention Description
Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
Primary Outcome Measure Information:
Title
Ventilator associated events
Description
A group of all the conditions that result in a significant and sustained deterioration in oxygenation, defined as a greater than 20% increase in the daily minimum fraction of inspired oxygen or an increase of at least 3 cm H2O in the daily minimum positive end-expiratory pressure (PEEP) to maintain oxygenation. It is imperative to understand that both infectious conditions (such as tracheitis, tracheobronchitis, and pneumonia) and noninfectious conditions (such as atelectasis, pulmonary embolism, pulmonary edema, ventilator-induced lung injury, and others) may fulfill this VAE definition.
Time Frame
24 hours after extubation
Secondary Outcome Measure Information:
Title
Adverse events
Description
Number of patientes with Bleeding and lacerations in the oropharynx
Time Frame
24 hours after extubation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Intubated adult patients with mechanical ventilation. To have a closest responsible relative Integrity of the airways Exclusion Criteria: Need of orofacial, cervical or respiratory tract surgical procedures Patients with tracheostomy Shock, Local or systemic uncontrolled infection Blood dyscrasia, neoplastic diseases Physiological alteration Acute or chronic decompensated pathology that is not controlled at the time of selection.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alba L Ramirez Sarmiento, PhD
Organizational Affiliation
Fundación Cardiovascular de Colombia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fundación Cardiovascular de Colombia
City
Piedecuesta
State/Province
Santander
ZIP/Postal Code
681011
Country
Colombia

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Evaluation of the Effectiveness and Safety of Supratube Device

We'll reach out to this number within 24 hrs